Procter & Gamble and Sanofi-Aventis seek stop to Boniva ads

Share this article:
Procter & Gamble and Sanofi-Aventis filed a lawsuit in Manhattan federal court Wednesday seeking an injunction to halt advertising for Roche and GlaxoSmithKline’s jointly marketed Boniva (ibandronate sodium). The lawsuit alleges the professional and consumer ads for Boniva falsely claim the drug has been proven to be more effective than Actonel (risedronate sodium tablets), jointly marketed by Procter & Gamble and Sanofi-Aventis. “The medications have not been compared in head-to-head clinical studies.” Procter & Gamble and Sanofi-Aventis said in a joint news release. “However, Boniva has not been proven to reduce the risk of nonspinal fracture.  In its pivotal clinical trial, there were a similar number of nonspinal osteoporotic fractures at 3 years in women treated with Boniva and placebo.” A spokeswoman for Roche in an Associated Press report that the firm “is confident the advertising accurately and appropriately reflects the clinical findings.” A spokeswoman for GlaxoSmithKline added in the published report that the company had yet to see the lawsuit but believed that its Boniva advertising “has been truthful and accurate.”
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...